FDA Approves Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris
Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, have announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1%. It is indicated for the topical treatment of acne vulgaris in patients twelve years of age and older.
Cabtreo offers three mechanisms of action, combining an antibiotic, retinoid and antibacterial, to provide a proven, safe, and effective treatment. It also has the potential to simplify dosing with a once daily topical acne treatment regimen.
Cabtreo is the first and only FDA-approved fixed-dose, triple-combination topical treatment for acne, and it is expected to be available to patients in Q1 2024.
